DAPACONIC 5MG TAB 15

About

DAPACONIC 5MG TAB contains Dapagliflozin 5mg, a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This medication is used for the management of type 2 diabetes mellitus, heart failure with reduced ejection fraction, and chronic kidney disease. Dapagliflozin works by inhibiting SGLT2 in the renal tubules, which reduces the reabsorption of glucose from the kidneys back into the bloodstream. This leads to increased glucose excretion in the urine, thereby lowering blood glucose levels. Beyond its glucose-lowering effects, dapagliflozin has demonstrated significant cardiovascular and renal protective benefits, reducing the risk of hospitalization for heart failure and slowing the progression of kidney disease. It is an important therapeutic option for patients needing comprehensive management of these interconnected conditions.

Uses

• Management of type 2 diabetes mellitus
• Treatment of heart failure with reduced ejection fraction
• Management of chronic kidney disease
• Reduction of cardiovascular and renal risks

Directions For Use

Take orally once daily, with or without food, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Effective in lowering blood glucose levels
• Supports weight reduction
• Reduces risk of major cardiovascular events
• Provides significant renal protective benefits
• Lowers blood pressure
• Convenient once-daily dosing

Side Effects

• Urinary tract infections
• Genital yeast infections
• Increased urination
• Thirst
• Dehydration
• Dizziness
• Nausea
• Constipation
• Ketoacidosis (rare)
• Fournier's gangrene (very rare)
• Hypoglycemia (when combined with insulin/sulfonylureas)
• Back pain

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of ketoacidosis, a serious side effect associated with SGLT2 inhibitors.
• Pregnancy - Not recommended during pregnancy. Consult your doctor immediately if you become pregnant or plan to conceive.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if dapagliflozin passes into breast milk. Consult your doctor.
• Liver - Use with caution in patients with severe hepatic impairment; data is limited, and close monitoring may be required.
• Kidney - Efficacy for glycemic control decreases with declining renal function. While indicated for CKD progression, it is not recommended for glycemic control below certain eGFRs.
• Lung - No specific direct lung contraindication.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.